Catalyst Event
Abbott Laboratories (ABT) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/24/2026, 12:00:00 AM
S&P Global Ratings downgraded Abbott's credit rating to 'A+' from 'AA-' on March 24, 2026, following the completion of the debt-financed acquisition of Exact Sciences, citing an expected increase in leverage to about 2.2x.
Korean Translation
2026년 3월 24일, S&P 글로벌 레이팅스는 이그잭트 사이언시스(Exact Sciences)의 부채 조달 인수 완료에 따라 애보트의 신용등급을 'AA-'에서 'A+'로 하향 조정함. 이는 레버리지가 약 2.2배로 증가할 것으로 예상되기 때문임.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release is scheduled; medium importance is estimated based on expected >=5% price impact.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
First quarter 2026 earnings release scheduled for April 30, 2026. Medium importance is estimated based on typical price volatility during earnings announcements, and the release is scheduled.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Other
The FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to meet on 2026-04-30 to review applications for camizestrant for breast cancer and a label expansion for Truqap in prostate cancer, scheduled.
4/30/2026, 12:00:00 AM